Ondansetron is used for: Prevention of nausea-vomiting associated with chemotherapy; Prevention of nausea & vomiting associated with radiotherapy; Prevention of post-operative nausea & vomiting; Nausea-vomiting in gastroenteritis; Nausea vomiting in pregnancy.
Recorded in the NepalDoc medicine catalog for Ondansetron.
Ondansetron oral solution is indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 initial and repeat courses of moderately emetogenic cancer chemotherapy radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron oral solution is also indicated for the prevention of postoperative nausea and/or vomiting.
From the U.S. FDA-approved label for Ondansetron. Full label: DailyMed.
Ondansetron oral solution is indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 initial and repeat courses of moderately emetogenic cancer chemotherapy radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen Ondansetron oral solution is also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron oral solution is a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2. nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. postoperative nausea and/or vomiting.
From the U.S. FDA-approved label for Ondansetron. Full label: DailyMed.
See full prescribing information for the recommended dosage in adults and pediatrics. Patients with severe hepatic impairment: do not exceed a total daily dose of 8 mg. 2.1 Dosage The recommended dosage regimens for adult and pediatric patients are described in Table 1 and Table 2, respectively.
Directions from the U.S. FDA-approved label for Ondansetron — your doctor or pharmacist may advise differently.
Ondansetron is contraindicated in patients: known to have hypersensitivity (e.g., anaphylaxis) to ondansetron or any of the components of the formulation receiving concomitant apomorphine due to the risk of profound hypotension and loss of consciousness Patients known to have hypersensitivity (e.g., anaphylaxis) to ondansetron or any components of the formulation. Concomitant use of apomorphine.
Excerpt from the U.S. FDA-approved label for Ondansetron. Talk to a pharmacist or doctor before use.
Hypersensitivity Reactions, Including Anaphylaxis and Bronchospasm: Discontinue ondansetron if suspected. Monitor and treat promptly per standard of care until signs and symptoms resolve. QT Interval Prolongation and Torsade de Pointes: Avoid ondansetron in patients with congenital long QT syndrome; monitor with electrocardiograms (ECGs) if concomitant electrolyte abnormalities, cardiac failure or arrhythmias, or use of other QT prolonging drugs. Serotonin Syndrome: Reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs.
Warnings and precautions excerpt from the U.S. FDA-approved label for Ondansetron — not a complete list. Talk to a pharmacist or doctor before use.
The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions QT Prolongation Serotonin Syndrome Myocardial Ischemia Masking of Progressive Ileus and Gastric Distension The most common adverse reactions in adults for the: prevention of chemotherapy-induced (≥ 5%) are: headache, malaise/fatigue, constipation, diarrhea.
Excerpt from the U.S. FDA-approved label for Ondansetron — not a complete list. Talk to a pharmacist or doctor about side effects.
47 brands · 24 makers in the NepalDoc catalog — see the full Ondansetron guide →
Protect from light.
Storage information from the U.S. FDA-approved label for Ondansetron.
What is Vomiset?
Vomiset 8mg Tablet is a Ondansetron medicine made by Time Pharmaceuticals Pvt. Ltd. It comes as 8mg Tablet.
What is Vomiset used for?
Ondansetron is used for Prevention of nausea-vomiting associated with chemotherapy, Prevention of nausea & vomiting associated with radiotherapy, Prevention of post-operative nausea & vomiting, Nausea-vomiting in gastroenteritis, Nausea vomiting in pregnancy.
What is the generic name of Vomiset?
The generic name of Vomiset is Ondansetron.
Which brands of Ondansetron are available in Nepal?
47 brands of Ondansetron are listed in the NepalDoc catalog, from 24 makers — including DANTRON 4MG Tablet, DANTRON 30 mg Syrup, DANTRON 8MG Tablet, Emeset 8mg+4ml Injection, Emeset 4mg Tablet, Emeset 8mg Tablet.
What are the side effects of Ondansetron?
The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions QT Prolongation Serotonin Syndrome Myocardial Ischemia Masking of Progressive Ileus and Gastric Distension The most common adverse reactions in adults for the: prevention of chemotherapy-induced (≥ 5%) are: headache, malaise/fatigue, constipation, diarrhea.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
